Economic impact of medication non-adherence by disease groups: a systematic review
Open accessThe DOI matches its Crossref record; 98 of the 113 references it cites were found in a registry or an index; 5 of the 59 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To determine the economic impact of medication non-adherence across multiple disease groups. DESIGN: Systematic review. EVIDENCE REVIEW: A comprehensive literature search was conducted in PubMed and Scopus in September 2017. Studies quantifying the cost of medication non-adherence in relation to economic impact were included. Relevant information was extracted and quality assessed using the Drummond checklist. RESULTS: Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included. Wide-scoping cost variations were reported, with lower levels of adherence generally associated with higher total costs. The annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44 190 (in 2015 US$). Costs attributed to 'all causes' non-adherence ranged from $5271 to $52 341. Medication possession ratio was the metric most used to calculate patient adherence, with varying cut-off points defining non-adherence. The main indicators used to measure the cost of non-adherence were total cost or total healthcare cost (83% of studies), pharmacy costs (70%), inpatient costs (46%), outpatient costs (50%), emergency department visit costs (27%), medical costs (29%) and hospitalisation costs (18%). Drummond quality assessment yielded 10 studies of high quality with all studies performing partial economic evaluations to varying extents. CONCLUSION: Medication non-adherence places a significant cost burden on healthcare systems. Current research assessing the economic impact of medication non-adherence is limited and of varying quality, failing to provide adaptable data to influence health policy. The correlation between increased non-adherence and higher disease prevalence should be used to inform policymakers to help circumvent avoidable costs to the healthcare system. Differences in methods make the comparison among studies challenging and an accurate estimation of true magnitude of the cost impossible. Standardisation of the metric measures used to estimate medication non-adherence and development of a streamlined approach to quantify costs is required. PROSPERO REGISTRATION NUMBER: CRD42015027338.
Overview
CoChat Summary
## TL;DR
This systematic review found that medication non-adherence is generally associated with higher healthcare costs across 14 disease groups, but the reported costs varied widely and could not be meaningfully pooled because of heterogeneity. Across 79 included studies, the adjusted annual disease-specific cost of non-adherence per person ranged from $949 to $44,190, and the authors concluded that standardised adherence and cost measures are needed.
## Key findings
- The review included 79 individual studies across 14 disease groups; search strategies retrieved 2768 records, 289 were full-text reviewed, and 79 were included.
- Reported annual adjusted disease-specific economic cost of non-adherence per person ranged from $949 to $44,190 (2015 US$); costs attributed to “all causes” non-adherence ranged from $5271 to $52,341.
- Across studies reporting total or total healthcare costs, 39 studies (49%) found non-adherence costs were greater than adherence costs, while 11 studies (15%) found the opposite.
- The most-used adherence metric was medication possession ratio (MPR), reported in 51 studies (63%); the next most common was proportion of days covered (PDC) at 11%.
- Quality assessment found 10 high-quality, 59 medium-quality, and 10 low-quality studies; no full economic evaluation was conducted in any included study.
## Methods
- Design: Systematic review conducted according to PRISMA and registered in PROSPERO (CRD42015027338).
- Data/sample: Searches were run in PubMed and Scopus in September 2017, with no publication date or language restrictions; included studies had to report the monetary cost of medication non-adherence for any disease state and provide original data.
- Main analysis: Two reviewers appraised studies using a modified Drummond checklist; costs were converted to 2015 US$, extracted by outcome indicator, and the authors attempted but could not perform a meta-analysis because of heterogeneity and missing statistical parameters.
## Limitations
- The paper states that a meta-analysis could not be performed because of heterogeneity in study design and lack of required statistical parameters, particularly standard deviations.
- The authors note that differences in methodological strategies, adherence definitions, and cost indicators made comparison across studies difficult and limited estimation of the true magnitude of costs.
- Evident from the text: the evidence base was dominated by US studies (66 of 79; 83%), and many studies were partial economic evaluations rather than full economic evaluations, which limits generalisability and comparability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
4 Valid · 0 Not valid · 58 Not checked · 72 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“While Zhao et al80 categorised participants into adherence subgroups, finding that total healthcare costs were lower for the non-adherent population.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Supportedcites [80] Zhao, 2014, Associations between statin adherence level, health care costs, and utilization, J Manag Care Spec Pharm source
The Statistical Analysis section divides participants into statin-adherence groups. The results report that the lowest-adherence group (MPR <40%) had lower estimated total health care costs over one year than every higher-adherence group; the difference was statistically significant for all but the 70%–79% group. This supports the citing sentence’s comparison, although the paper uses a specific low-adherence group rather than a single category of all non-adherent patients. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“One study measured the influence of medication non-adherence on direct healthcare costs in metabolic conditions, reporting an unadjusted attributable total cost of $138 525.54”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [54] matched to “Association of cinacalcet adherence and costs in patients on dialysis” (2011) sourceExperimental — accuracy not yet measured
The Methods and Results report an analysis of cinacalcet adherence and direct healthcare costs in dialysis patients with secondary hyperparathyroidism, including unadjusted 12-month costs. The Results refer to a table of mean costs, but the values are absent from our copy; no passage verifies the claimed $138,525 unadjusted attributable total cost. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The findings were that, for all levels of non-adherence, costs of non-adherence were higher for Medicare supplemental patients.45”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Cost of medication non-adherence via disease group
What the sources say
- Partly supportedcites [45] Halpern, 2011, The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis, J Manag Care Pharm sourceExperimental — accuracy not yet measured
The medical-cost results (page unavailable) report higher adjusted costs with low versus high adherence in both groups, with a larger percentage increase in Medicare Advantage patients (18%) than commercial patients (12%). Moderate adherence was also associated with higher costs in the Medicare Advantage group, but not significantly in the commercial group. The claim calls these patients “Medicare supplemental” rather than Medicare Advantage and does not specify that the comparison concerns adjusted percentage increases, so its broader cost comparison is not established. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Seventy-nine individual studies assessing the cost of medication non-adherence across 14 disease groups were included.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted total cost of non-adherence across all disease groups ranged from $949 to $52 341, while the unadjusted total cost ranged from $669 to $162 699.”
§ Economic impact of medication non-adherence by disease groups: a systematic review > Results > Medication non-adherence and costs
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
67 more claims
Create a free account to see all 134 claims and every source verdict.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 28
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Medication non-adherence is a widespread problem that causes high costs worldwide [5–10].”
From Medication adherence influencing factors—an (updated) overview of systematic reviews (2019) · cites this paper as [6]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Furthermore, a person-centered approach predicts better outcomes, such as fewer relapses, suicide and overall mortality [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Only then will it be possible to contribute to the improvement of clinical and social outcomes, generate commitment, and guarantee a quality of services that translates into increased adherence rates and reduced number of hospitalizations and all associated costs (including pharmacy costs and inpatient and outpatient costs) [91].”
From Therapeutic Adherence of People with Mental Disorders: An Evolutionary Concept Analysis (2023) · cites this paper as [91]
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Methods for the Economic Evaluation of Health Care Programmes
Drummond, M. E., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005) · doi:10.1093/oso/9780198529446.001.0001 · Cited by 13,648
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Guidelines for authors and peer reviewers of economic submissions to the BMJ
Drummond, M. F., & Jefferson, T. O. (1996) · BMJ · doi:10.1136/bmj.313.7052.275 · Cited by 1,827
Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost
Sokol, M. C., McGuigan, K. A., Verbrugge, R. R., & Epstein, R. S. (2005) · Medical Care · doi:10.1097/01.mlr.0000163641.86870.af · Cited by 1,729 · cited 4×
“The adjusted cost of medication non-adherence was reported in 14 studies with an estimated range of $5271–52 341.(10) 29 31 56 58–60 70 75 76 83 84 86 90 Sokol et al(10) reported the all-cause cost of non-adherence through subgroup analysis of disease states and MPR levels, while Pittman et al(60) reported only using…”
BackgroundMethodInfluentialInterventions for helping patients to follow prescriptions for medications
Haynes, R., McDonald, H., Garg, A., & Montague, P. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000011 · Cited by 911
Hess, L. M., Raebel, M. A., Conner, D. A., & Malone, D. C. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h018 · Cited by 756
Gilmer, T. P., Dolder, C. R., Lacro, J. P., Folsom, D. P., Lindamer, L., Garcia, P., & Jeste, D. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.692 · Cited by 603 · cited 2×
“65 81 98 Six studies used adjusted costs, finding that the total annual cost of non-adherence per patient ranged from $3252 to $19 363.(23) 25 58 59 72 90 Bagalman et al(25) focused primarily on”
BackgroundResult
Cited by
Items 301–400 of 881
Use of Interventions to Overcome Medication Non-Adherence
Saha, S. K., Adhikary, A., Jha, A. K., & Mehta, V. K. (2021) · International Journal of Asian Business and Information Management · doi:10.4018/ijabim.20210701.oa18 · Cited by 10
Leino, A. D., Kaiser, T. E., Khalil, K., Mansell, H., & Taber, D. J. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.01.023 · Cited by 16
Forma, F. M., Green, T., Kim, S., & Teigland, C. L. (2020) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s231000 · Cited by 16
Park, K. H., Tickle, L., & Cutler, H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269836 · Cited by 10
Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study
Sportoletti, P., Laurenti, L., Chiarenza, A., Gaïdano, G., Albi, E., Mauro, F. R., Trentin, L., Vallisa, D., Pane, F., Cuneo, A., et al. (2023) · Hematological Oncology · doi:10.1002/hon.3216 · Cited by 12
Dima, A. L., Allemann, S. S., & Dediu, D. (2019) · Studies in health technology and informatics · doi:10.3233/shti190479 · Cited by 10
Adherence of patients with diabetic macular oedema to intravitreal injections: A systematic review
Rose, M. A., Vukicevic, M., & Koklanis, K. (2020) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13845 · Cited by 9
Chow, S. M., & Tan, B. K. (2024) · Supportive Care in Cancer · doi:10.1007/s00520-024-08635-8 · Cited by 20
Couzos, S., Smith, D., Stephens, M., Preston, R., Hendrie, D. V., Loller, H., Tremlett, M., Nugent, A., Vaughan, F., Crowther, S. P., et al. (2019) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2019.12.022 · Cited by 11
Alyami, M. M., Serlachius, A. S., Law, M., Murphy, R., Almigbal, T. H., Lyndon, M., Batais, M. A., Algaw, R. K., & Broadbent, E. (2022) · JMIR Formative Research · doi:10.2196/35079 · Cited by 13
Brennan, V., Mulvey, C., Greene, G., MacHale, E., & Costello, R. W. (2021) · Frontiers in Medical Technology · doi:10.3389/fmedt.2021.604475 · Cited by 8
Perceived Financial Insecurity Impacts Healthcare Decision‐Making Among Patients With Sinusitis
Pandrangi, V. C., Farrell, N. F., Mace, J. C., Detwiller, K. Y., Smith, T. L., & Geltzeiler, M. N. (2021) · The Laryngoscope · doi:10.1002/lary.29561 · Cited by 11
Kardas, P., & Ágh, T. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1714049 · Cited by 10
Ingrasciotta, Y., Vitturi, G., & Trifirò, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072113 · Cited by 11
Rampamba, E., Meyer, J., Helberg, E., & Godman, B. (2020) · Journal of Research in Pharmacy Practice · doi:10.4103/jrpp.jrpp_20_49 · Cited by 6
An analytical model to evaluate reminders for medication adherence
Varshney, U., & Singh, N. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2020.104091 · Cited by 8
Pezzolato, M., Marzorati, C., Lanzoni, L., Monzani, D., Masiero, M. A., Pietrobon, R. S., & Pravettoni, G. (2023) · Psycho-Oncology · doi:10.1002/pon.6203 · Cited by 11
Chevance, A., Fortel, A., Jouannin, A., Denis, F., Mamzer, M., Ravaud, P., & Sidorkiewicz, S. (2022) · Journal of Medical Internet Research · doi:10.2196/25597 · Cited by 10
Wong, R., Mehta, T., Very, B., Luo, J., Feterik, K., Crotty, B. H., Epstein, J. A., Fliotsos, M. J., Kashyap, N., Smith, E., et al. (2022) · Journal of General Internal Medicine · doi:10.1007/s11606-022-07945-z · Cited by 13
Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs
Lasala, R., Santoleri, F., Romagnoli, A., Abrate, P., Musicco, F., & Costantini, A. (2022) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2021-002998 · Cited by 9
Hong, M., Esse, T. W., Vadhariya, A., Gallardo, E., Fosshat, M. A., Mamvou, J., Castel, L. D., Serna, O., & Abughosh, S. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.5.662 · Cited by 10
Mitello, L., Marti, F., Mauro, L., Siano, L., Pucci, A., Tarantino, C., Rocco, G., Stievano, A., Iacorossi, L., Anastasi, G., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154374 · Cited by 11
Wells, J. S., Crilly, P., & Kayyali, R. (2022) · Patient Preference and Adherence · doi:10.2147/ppa.s375745 · Cited by 11
Ellis, R. J. B., Andrews, A. M., Elomba, C. D., Remy, L. M., Ruggeri, S. Y., Russell, C. L., & Ruppar, T. M. (2023) · Patient Preference and Adherence · doi:10.2147/ppa.s393749 · Cited by 11
Kim, J., Kassels, A. C., Costin, N. I., & Schmidt, H. (2020) · Journal of Medical Ethics · doi:10.1136/medethics-2019-105667 · Cited by 9
Jones, M., Moffatt, F., Harvey, A., & Ryan, J. M. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013610.pub2 · Cited by 16
Factors predicting medication adherence among coronary artery disease patients in Saudi Arabia
Almarwani, A. M., & Almarwani, B. M. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.9.20230293 · Cited by 9
Chapman, S., Frostholm, L., Chalder, T., Graham, C. D., de Thurah, A. L., van Leeuwen, T., Pedersen, M. M., Carstensen, T. B. W., & Weinman, J. A. (2024) · Health Psychology Review · doi:10.1080/17437199.2024.2385525 · Cited by 13
Kim, K., Hong, S., Han, K., & Park, C. (2024) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2024.13.1.41 · Cited by 13
Chua, B. W. B., Morgan, J., & Yap, K. Z. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062133 · Cited by 12
Park, K. H., Tickle, L., & Cutler, H. (2021) · SSM - Population Health · doi:10.1016/j.ssmph.2021.100973 · Cited by 10
Faktor-Faktor yang Mempengaruhi Ketaatan Minum Obat pada Penyakit Kronik
Farisi, M. A. (2020) · Jurnal Ilmiah Universitas Batanghari Jambi · doi:10.33087/jiubj.v20i1.883 · Cited by 18
Granata, N., Traversoni, S., Kardas, P., Kurczewska-Michalak, M., Costa, E. M., Midão, L., & Giardini, A. (2020) · Patient Education and Counseling · doi:10.1016/j.pec.2020.04.006 · Cited by 16
Sbarigia, U., Kariburyo, F., Sah, J., Colasurdo, J., Xie, L., Katz, E. G., & Sylvester, S. V. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01240-1 · Cited by 12
Shahabi, N. A., Javdan, G., Hosseini, Z., Aghamolaei, T., Ghanbarnejad, A., & Behzad, A. (2024) · BMC Public Health · doi:10.1186/s12889-024-19452-3 · Cited by 21
Lukina, Y. V., Кутишенко, Н. П., Martsevich, S. Y., & Drapkina, O. M. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3603 · Cited by 11
Jeun, K. J., Nduaguba, S. O., & Al-Mamun, M. A. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231210284 · Cited by 10
Yousuf, F. S., Khan, M. A. A., Bibi, R., Arif, A., Arshad, A., & Almas, A. (2023) · Cureus · doi:10.7759/cureus.33995 · Cited by 9
Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization
Novi, C. D., Leporatti, L., Levaggi, R., & Montefiori, M. (2022) · Journal of Economic Behavior & Organization · doi:10.1016/j.jebo.2022.10.012 · Cited by 9
Dashputre, A. A., Gatwood, K. S., Schmidt, J., & Gatwood, J. D. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219875206 · Cited by 8
Lorcaserin in obesity: minimal benefits and ill-defined harms
Onakpoya, I., & Aronson, J. K. (2019) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2018-111128 · Cited by 9
Reevaluating medication adherence in the era of digital health
Aungst, T. D. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.2019012 · Cited by 11
Vilaplana-Carnerero, C., Aznar‐Lou, I., Peñarrubia‐María, M. T., Serrano‐Blanco, A., Fernández‐Vergel, R., Petitbò-Antúnez, D., Gil‐Girbau, M., March-Pujol, M., Mendive, J. M., Sánchez‐Viñas, A., et al. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103358 · Cited by 12
Moondra, P., & Shahed, J. J. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2376107 · Cited by 8
Mobile Health Platforms for Medication Adherence among Oncology Patients in Rural Populations
Atalor, S. I., & Enyejo, J. O. (2025) · doi:10.38124/ijisrt/25may415 · Cited by 22
Killey, J., Simons, M., & Tyack, Z. F. (2020) · Clinical Rehabilitation · doi:10.1177/0269215520978528 · Cited by 10
Treatment-resistant depression and intranasal esketamine: Spanish consensus on theoretical aspects
Mora, F., Ramos‐Quiroga, J. A., Baca‐García, E., Crespo, J. M., Gutiérrez-Rojas, L., Madrazo, A., Pérez-Costillas, L., Sáiz, P. A., Tordera, V., & Vieta, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1623659 · Cited by 11
Machine learning approaches to predicting medication nonadherence: a scoping review
Rhudy, C. N., Johnson, J. D., Perry, C. L., Bumgardner, C., Wesley, M. J., Fardo, D. W., Barrett, T. A., & Talbert, J. (2025) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2025.106082 · Cited by 13
Jamshidi, A., Daroudi, R., Aas, E., & Khalili, D. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1075277 · Cited by 8
Ahmed, A., Dujaili, J. A., Chuah, L., Hashmi, F. K., Le, L. K., Khanal, S., Awaisu, A., & Chaiyakunapruk, N. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00818-4 · Cited by 9
Direct oral anticoagulants and therapeutic adherence: do not let your guard down
Gennaro, L. D., Monaco, M. L., Riccio, C., Candia, E. D., Alberelli, M. A., di Martino, C., Basso, M., Ferretti, M. A., Lancellotti, S., & CRISTOFARO, R. D. (2021) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2021.1908702 · Cited by 8
Zewdie, S., Mekuria, B., Alemu, B. K., Bayked, E. M., Toleha, H. N., Ayenew, W. A., & Andargie, A. (2024) · World Allergy Organization Journal · doi:10.1016/j.waojou.2024.100870 · Cited by 9
Alhomoud, F. K., Alwohaibi, L., Aljarrash, K., Alhomoud, F., Alamer, K. A., Alsultan, M. M., Alqarni, Y. S., Alotaibi, N., Alsaad, A., Alqahtani, A., et al. (2024) · Patient Preference and Adherence · doi:10.2147/ppa.s499795 · Cited by 8
Jacobs, C. M., Kunz, M., Mahfoud, F., Wagmann, L., & Meyer, M. R. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04394-9 · Cited by 11
Mittal, M., Yang, M., Shah, M., Gao, W., Carley, C., & Sherman, B. W. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002354 · Cited by 8
Vaitkienė, G., Kuzborska, Z., & Žukauskıenė, M. (2022) · Journal of Ageing and Longevity · doi:10.3390/jal2030016 · Cited by 11
Integrating Pharmacy and Registry Data Strengthens Clinical Assessments of Patient Adherence
Serhal, S., Armour, C. L., Billot, L., Krass, I., Emmerton, L., Saini, B., Bosnic-Anticevich, S. Z., Bereznicki, B. J., Bereznicki, L., Shan, S., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.869162 · Cited by 8
Plaitano, E. G., McNeish, D., Bartels, S. M., Bell, K. R., Dallery, J., Grabinski, M. J., Kiernan, M., Lavoie, H. A., Lemley, S. M., Lowe, M. R., et al. (2025) · Frontiers in Digital Health · doi:10.3389/fdgth.2025.1467772 · Cited by 10
Larsen, R. E., Pripp, A. H., Krogstad, T., Landmark, C. J., & Holm, L. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.981368 · Cited by 14
Wirbka, L., Haefeli, W. E., & Meid, A. D. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s324315 · Cited by 9
Patel, T., McDougall, A., Ivo, J., Carducci, J., Pritchard, S. J., Chang, F., Faisal, S., & Lee, C. (2021) · Pharmacy · doi:10.3390/pharmacy9020078 · Cited by 8
Underwood, M., & Ronald, K. (2020) · Currents in Pharmacy Teaching and Learning · doi:10.1016/j.cptl.2020.04.020 · Cited by 8
The offset effect of pharmaceutical innovation: A review study
Zozaya, N., Alcalá, B., & Galindo, J. (2019) · Global & Regional Health Technology Assessment · doi:10.1177/2284240319875108 · Cited by 14
Abeck, F., Hansen, I., Wiesenhütter, I., Brookman-May, S. D., Sharaf, K., Kött, J., Bertlich, M., Schneider, S. W., & von Büren, J. (2023) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2022.0290 · Cited by 9
Hanlon, M. L. D., Hogan, M., Durand, H., Pilch, M., Harney, O., Molloy, G. J., & Murphy, A. W. (2020) · HRB Open Research · doi:10.12688/hrbopenres.13110.2 · Cited by 8
Mehta, P., Pan, Z., Zhou, W., Kwan, B. M., & Furuta, G. T. (2023) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000003885 · Cited by 7
Commentary: The Impact of Digital Technology on Psychological Treatments and Their Dissemination
Heeren, A. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01571 · Cited by 10
Brooks, B. D., Job, S. A., Kaniuka, A. R., Kolb, R., Charvel, P. U., & Araújo, F. (2023) · Psychology and Health · doi:10.1080/08870446.2023.2220008 · Cited by 9
Xu, J., Zhao, X., Li, F., Xiao, Y., & Li, K. (2024) · Journal of Clinical Nursing · doi:10.1111/jocn.17577 · Cited by 10
Klein, P. J., Aebi, M. E., Sajatovic, M., Depp, C. A., Moore, D. J., Blixen, C. E., & Levin, J. B. (2020) · Journal of Behavioral and Cognitive Therapy · doi:10.1016/j.jbct.2020.03.015 · Cited by 8
Kassaw, E. A., Sendekie, A. K., Enyew, B. M., & Abate, B. B. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1486350 · Cited by 14
Engler, K., Vicente, S., Mate, K., Lessard, D., Ahmed, S., & Lebouché, B. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00435-0 · Cited by 8
Corral‐Partearroyo, C., Sánchez‐Viñas, A., Gil‐Girbau, M., Peñarrubia‐María, M. T., Aznar‐Lou, I., Gallardo‐Gonzalez, C., Olmos-Palenzuela, M. D. C., & Rubio-Valera, M. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067468 · Cited by 11
Purić, D., Petrović, M., Živanović, M., Lukić, P., Zupan, Z., Branković, M., Ninković, M., Lazarević, L. B., Stanković, S., & Žeželj, I. L. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-069978 · Cited by 8
Gebremichael, L. G., Beleigoli, A. M. R., Champion, S., Nesbitt, K., Bulto, L. N., de Plaza, M. A. P., Pearson, V., Noonan, S., Hendriks, J., Hines, S. J., et al. (2022) · JBI Evidence Synthesis · doi:10.11124/jbies-21-00457 · Cited by 7
Italian Translation and Validation of the Original ABC Taxonomy for Medication Adherence
Mucherino, S., Maffoni, M., Cena, C., Armando, L. G., Guastavigna, M., Orlando, V., Orofino, G., Traina, S., Giardini, A., Menditto, E., et al. (2023) · Healthcare · doi:10.3390/healthcare11060846 · Cited by 11
Primary medication nonadherence to oral oncology specialty medications
Zuckerman, A. D., Shah, N. B., Perciavalle, K., Looney, B. D., Peter, M. E., DeClercq, J., Moore, R. P., Choi, L., & Reynolds, V. W. (2022) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2022.01.005 · Cited by 7
Naeck-Boolauky, P., Adio, J., & Burch, J. (2020) · British Journal of Nursing · doi:10.12968/bjon.2020.29.14.805 · Cited by 7
Lopes, A. C., Roque, F., Morgado, S., Dinis, C., Herdeiro, M. T., & Morgado, M. (2021) · Behavioral Sciences · doi:10.3390/bs11110153 · Cited by 14
Bülbüloğlu, S., & Guneş, H. (2024) · EXPLORE · doi:10.1016/j.explore.2024.01.005 · Cited by 7
Ágh, T., Garuolienè, K., Granås, A. G., Gregório, J., Aksoy, N., Khanyk, N., Hadžiabdić, M. O., Kardas, P., & European Network to Advance Best Practices and Technology on Medication Adherence (ENABLE) Collaborators (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1390629 · Cited by 11
Hanlon, M. L. D., Hogan, M., Durand, H., Pilch, M., Harney, O., Molloy, G. J., & Murphy, A. W. (2020) · HRB Open Research · doi:10.12688/hrbopenres.13110.1 · Cited by 7
Patient preference and Long-term outcome of renal denervation for resistant hypertension
Ogoyama, Y., & Kario, K. (2022) · Hypertension Research · doi:10.1038/s41440-022-00962-9 · Cited by 7
Costs of Prescription Drugs for Children and Parental Adherence to Long-Term Medications
Lauffenburger, J. C., Barlev, R. A., Olatunji, E., Brill, G. E., & Choudhry, N. K. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.37971 · Cited by 7
Impact of patient-centered prescription medication labels on adherence in community pharmacy
Young, H. N., Pathan, F., Hudson, S., Mott, D. A., Smith, P. D., & Schellhase, K. G. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.01.004 · Cited by 10
Estimating optimal thresholds for adherence to RASA medications among older adults with hypertension
Parikh, M. A., Ramachandran, S., Nsiah, I., Campbell, P. J., Castora‐Binkley, M., Karmakar, T., Black, H. L., & Bentley, J. P. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.1.25 · Cited by 9
An Overview on the Pharmaceutical Applications of Nanocellulose
Kamel, R., & ElKasabgy, N. A. (2023) · Composites science and technology · doi:10.1007/978-981-99-2473-8_13 · Cited by 9
Racial Disparities in Patient Activation: The Role of Economic Diversity
Holt, J. M., Winn, A. N., Cusatis, R. N., Talsma, A., & Crotty, B. H. (2020) · Western Journal of Nursing Research · doi:10.1177/0193945920963130 · Cited by 9
Smaldone, A. M., Manwani, D. G., Aygün, B., Appiah‐Kubi, A., Smith‐Whitley, K., & Green, N. (2024) · Pediatric Blood & Cancer · doi:10.1002/pbc.31170 · Cited by 6
Defining, measuring, and addressing medication non-adherence in cardiovascular disease
Livori, A., Dalli, L. L., Nicholls, S. J., & Nelson, A. J. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2433888 · Cited by 8
Moges, T. A., Dagnew, S. B., Wondm, S. A., Ferede, Y. A., Yiblet, T. G., Almaw, A., Yimer, Y. S., Addis, G. T., Zewdu, W. S., & Dagnew, F. N. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1409153 · Cited by 9
Abbas, H., Hallit, S. R., Kurdi, M., & Karam, R. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02907-z · Cited by 8
Cho, J., Wilson, F. A., Chaikledkaew, U., Chen, Y., Phrommintikul, A., Díaz-Aguilera, M. Á., Chen, Z., Kim, K., & Chaiyakunapruk, N. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037792 · Cited by 10
Stakeholders’ Perspectives on Medication Adherence Enhancing Interventions
Borah, B. J., Pieretti, L. J., Balch, A. J., Wani, R. J., Daly, C. J., Dawoud, D., Hutchins, D. S., Hiligsmann, M., Peterson, A. M., & Ágh, T. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.022 · Cited by 9
Metadata
- Authors
- Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V.
- Affiliations
- University of Technology Sydney (AU)
- Department of Social Pharmacy Faculty of Pharmacy, Research Institute for Medicines (iMed.ULisboa), University of Lisbon, Lisbon, Portugal
- The University of Sydney (AU)
- Graduate School of Health, University of Technology Sydney, Sydney, New South Wales, Australia
- Corresponding author
- Cutler, Rachelle Louise
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2018-01
- Volume
- 8
- Issue
- 1
- Pages
- e016982
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC5780689
- OpenAlex
- W2790318238
- Cited by
- 900
- References
- 113
- Citations by year
- 2026: 83 · 2025: 111 · 2024: 159 · 2023: 134 · 2022: 112 · 2021: 124 · 2020: 91 · 2019: 68 · 2018: 16
- FWCI
- 16.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OPUS - Open Publications of UTS Scholars (University of Technology Sydney) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Australian Government
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- medication non-adherence, economic burden, health care costs, medication possession ratio, adherence measurement, health policy
- MeSH terms
- Cost-Benefit Analysis, Disease, Drug Therapy, Humans, Drug Monitoring, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.